1
NAPSRx CNPR Exam (Revised 18th
Edition)Actual Exam Questions &
Verified Answers | Pharmaceutical Sales
Certification Prep
Section 1: FDA Regulations & Drug Approval Process
Q1: Which FDA submission is required before a sponsor may proceed with a first-in-human
trial?
A. IND
B. NDA
C. ANDA
D. BLA
**Answer: A
Verified Rationale: An Investigational New Drug (IND) application must be approved by FDA
before Phase I human testing can begin.
Q2: The primary scientific objective of a Phase III trial is to:
A. Determine maximum tolerated dose.
B. Establish short-term safety in healthy volunteers.
C. Demonstrate statistically significant efficacy and continued safety in a large patient
population.
D. Monitor rare adverse events post-approval.
**Answer: C
Verified Rationale: Phase III trials are large, controlled studies designed to confirm therapeutic
benefit and overall risk-benefit profile.
Q3: Accelerated Approval regulations allow the FDA to grant marketing authorization based on:
A. Surrogate endpoints reasonably likely to predict clinical benefit.
B. Post-marketing commitments only.
C. Phase I pharmacokinetic data.
D. Foreign clinical data alone.
,2
**Answer: A
Verified Rationale: Accelerated Approval uses surrogate markers (e.g., lab values) that are
reasonably likely to predict ultimate patient benefit.
Q4: Which FDA advisory committee is most likely to review a new anticoagulant?
A. Anesthetic and Life Support Drugs.
B. Peripheral and Central Nervous System Drugs.
C. Cardiovascular and Renal Drugs.
D. Antimicrobial Drugs.
**Answer: C
Verified Rationale: Anticoagulants fall within the cardiovascular therapeutic area reviewed by
the Cardiovascular and Renal Drugs Advisory Committee.
Q5: The “Letter of No Objection” issued by FDA’s OPDP relates to:
A. Patent certification.
B. Promotional labeling or advertising pieces.
C. Clinical hold removal.
D. Manufacturing site change.
**Answer: B
Verified Rationale: Office of Prescription Drug Promotion issues letters when promotional
materials raise no objectionable claims.
Q6: A sponsor must file an IND amendment for which protocol change?
A. Change in study monitor.
B. 15% increase in study enrollment.
C. New toxicology study showing severe renal findings.
D. Switch from capsules to tablets with identical API.
**Answer: C
Verified Rationale: New significant toxicology data that affects human risk must be reported as
an IND amendment within 15 days.
Q7: The Pediatric Research Equity Act (PREA) requires:
A. Pediatric efficacy supplements for all marketed drugs.
B. Pediatric studies for drugs likely to be used in children unless waived.
C. Waivers for all oncology drugs.
D. Deferral until 5 years post-approval.
**Answer: B
Verified Rationale: PREA mandates pediatric assessments unless full or partial waivers are
granted.
, 3
Q8: A “breakthrough therapy designation” is granted when preliminary evidence indicates the
drug may offer:
A. 10% improvement over placebo.
B. Substantial improvement on clinically significant endpoints over available therapy.
C. Cost savings of ≥20%.
D. Generic substitution capability.
**Answer: B
Verified Rationale: Breakthrough status requires substantial improvement on a clinically
significant endpoint.
Q9: Which phase is primarily used to support dosing instructions in the proposed package insert?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
**Answer: C
Verified Rationale: Dose-ranging and confirmation of optimal dose occur mainly in Phase III.
Q10: The FDA’s “Sentinel Initiative” is a system for:
A. Active surveillance of adverse events using electronic healthcare data.
B. Recruiting patients for Phase I trials.
C. Reviewing advertising layouts.
D. Approving compassionate-use protocols.
**Answer: A
Verified Rationale: Sentinel actively monitors marketed products using large automated
healthcare databases.
Section 2: Pharmacology & Therapeutic Drug Classes
Q11: A drug that functions as a selective aldosterone antagonist is:
A. Furosemide
B. Spironolactone
C. Acetazolamide
D. Mannitol
**Answer: B
Verified Rationale: Spironolactone blocks mineralocorticoid receptors, reducing aldosterone
activity.
Q12: Which class increases insulin secretion by closing ATP-sensitive potassium channels in β-
cells?
A. Biguanides
NAPSRx CNPR Exam (Revised 18th
Edition)Actual Exam Questions &
Verified Answers | Pharmaceutical Sales
Certification Prep
Section 1: FDA Regulations & Drug Approval Process
Q1: Which FDA submission is required before a sponsor may proceed with a first-in-human
trial?
A. IND
B. NDA
C. ANDA
D. BLA
**Answer: A
Verified Rationale: An Investigational New Drug (IND) application must be approved by FDA
before Phase I human testing can begin.
Q2: The primary scientific objective of a Phase III trial is to:
A. Determine maximum tolerated dose.
B. Establish short-term safety in healthy volunteers.
C. Demonstrate statistically significant efficacy and continued safety in a large patient
population.
D. Monitor rare adverse events post-approval.
**Answer: C
Verified Rationale: Phase III trials are large, controlled studies designed to confirm therapeutic
benefit and overall risk-benefit profile.
Q3: Accelerated Approval regulations allow the FDA to grant marketing authorization based on:
A. Surrogate endpoints reasonably likely to predict clinical benefit.
B. Post-marketing commitments only.
C. Phase I pharmacokinetic data.
D. Foreign clinical data alone.
,2
**Answer: A
Verified Rationale: Accelerated Approval uses surrogate markers (e.g., lab values) that are
reasonably likely to predict ultimate patient benefit.
Q4: Which FDA advisory committee is most likely to review a new anticoagulant?
A. Anesthetic and Life Support Drugs.
B. Peripheral and Central Nervous System Drugs.
C. Cardiovascular and Renal Drugs.
D. Antimicrobial Drugs.
**Answer: C
Verified Rationale: Anticoagulants fall within the cardiovascular therapeutic area reviewed by
the Cardiovascular and Renal Drugs Advisory Committee.
Q5: The “Letter of No Objection” issued by FDA’s OPDP relates to:
A. Patent certification.
B. Promotional labeling or advertising pieces.
C. Clinical hold removal.
D. Manufacturing site change.
**Answer: B
Verified Rationale: Office of Prescription Drug Promotion issues letters when promotional
materials raise no objectionable claims.
Q6: A sponsor must file an IND amendment for which protocol change?
A. Change in study monitor.
B. 15% increase in study enrollment.
C. New toxicology study showing severe renal findings.
D. Switch from capsules to tablets with identical API.
**Answer: C
Verified Rationale: New significant toxicology data that affects human risk must be reported as
an IND amendment within 15 days.
Q7: The Pediatric Research Equity Act (PREA) requires:
A. Pediatric efficacy supplements for all marketed drugs.
B. Pediatric studies for drugs likely to be used in children unless waived.
C. Waivers for all oncology drugs.
D. Deferral until 5 years post-approval.
**Answer: B
Verified Rationale: PREA mandates pediatric assessments unless full or partial waivers are
granted.
, 3
Q8: A “breakthrough therapy designation” is granted when preliminary evidence indicates the
drug may offer:
A. 10% improvement over placebo.
B. Substantial improvement on clinically significant endpoints over available therapy.
C. Cost savings of ≥20%.
D. Generic substitution capability.
**Answer: B
Verified Rationale: Breakthrough status requires substantial improvement on a clinically
significant endpoint.
Q9: Which phase is primarily used to support dosing instructions in the proposed package insert?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
**Answer: C
Verified Rationale: Dose-ranging and confirmation of optimal dose occur mainly in Phase III.
Q10: The FDA’s “Sentinel Initiative” is a system for:
A. Active surveillance of adverse events using electronic healthcare data.
B. Recruiting patients for Phase I trials.
C. Reviewing advertising layouts.
D. Approving compassionate-use protocols.
**Answer: A
Verified Rationale: Sentinel actively monitors marketed products using large automated
healthcare databases.
Section 2: Pharmacology & Therapeutic Drug Classes
Q11: A drug that functions as a selective aldosterone antagonist is:
A. Furosemide
B. Spironolactone
C. Acetazolamide
D. Mannitol
**Answer: B
Verified Rationale: Spironolactone blocks mineralocorticoid receptors, reducing aldosterone
activity.
Q12: Which class increases insulin secretion by closing ATP-sensitive potassium channels in β-
cells?
A. Biguanides
